chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine used; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in an 18-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jun-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications details were not reported by the reporter. Treatment details was not reported by the reporter.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Inappropriate schedule of product administration, Muscle spasms
Clinical narrative: leg cramps; arm soreness/soreness of the site; head is pounding; chills; 38 days between the first and second dose of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (38 days between the first and second dose of the vaccine), MUSCLE SPASMS (leg cramps), VACCINATION SITE PAIN (arm soreness/soreness of the site), HEADACHE (head is pounding) and CHILLS (chills) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 93989B and 015621A or 0512H) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included AMLODIPINE for Hypertension.   On 18-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Jul-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (38 days between the first and second dose of the vaccine). 27-Jul-2021, the patient experienced VACCINATION SITE PAIN (arm soreness/soreness of the site), HEADACHE (head is pounding) and CHILLS (chills). On an unknown date, the patient experienced MUSCLE SPASMS (leg cramps). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (38 days between the first and second dose of the vaccine), MUSCLE SPASMS (leg cramps), VACCINATION SITE PAIN (arm soreness/soreness of the site), HEADACHE (head is pounding) and CHILLS (chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Jul-2021, Body temperature: 101.2 (Inconclusive) oral temperature was 101.2 degrees Fahrenheit.         No treatment medications were reported. After the first dose patient had soreness of the site. She has arm soreness today and 2 hours ago. She had headaches and her head is pounding. 30 minutes ago she started having chills and took her oral temperature which was 101.2 degrees Fahrenheit. She hasn't eaten or drank anything. She also has leg cramps. She intends to take ibuprofen for her side effects.   This case was linked to MOD-2021-270098 (Patient Link).
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: leg cramps; arm soreness/soreness of the site; head is pounding; chills; 38 days between the first and second dose of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (38 days between the first and second dose of the vaccine), MUSCLE SPASMS (leg cramps), VACCINATION SITE PAIN (arm soreness/soreness of the site), HEADACHE (head is pounding) and CHILLS (chills) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 93989B and 015621A or 0512H) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included AMLODIPINE for Hypertension.   On 18-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Jul-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (38 days between the first and second dose of the vaccine). 27-Jul-2021, the patient experienced VACCINATION SITE PAIN (arm soreness/soreness of the site), HEADACHE (head is pounding) and CHILLS (chills). On an unknown date, the patient experienced MUSCLE SPASMS (leg cramps). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (38 days between the first and second dose of the vaccine), MUSCLE SPASMS (leg cramps), VACCINATION SITE PAIN (arm soreness/soreness of the site), HEADACHE (head is pounding) and CHILLS (chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Jul-2021, Body temperature: 101.2 (Inconclusive) oral temperature was 101.2 degrees Fahrenheit.         No treatment medications were reported. After the first dose patient had soreness of the site. She has arm soreness today and 2 hours ago. She had headaches and her head is pounding. 30 minutes ago she started having chills and took her oral temperature which was 101.2 degrees Fahrenheit. She hasn't eaten or drank anything. She also has leg cramps. She intends to take ibuprofen for her side effects.   This case was linked to MOD-2021-270098 (Patient Link).
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza, Product dose omission issue
Clinical narrative: "got sick with the flu" around the time of their scheduled 2nd dose which was 19Jun2021; Did not get 2nd dose yet; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA ("got sick with the flu" around the time of their scheduled 2nd dose which was 19Jun2021) and PRODUCT DOSE OMISSION ISSUE (Did not get 2nd dose yet) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA ("got sick with the flu" around the time of their scheduled 2nd dose which was 19Jun2021) and PRODUCT DOSE OMISSION ISSUE (Did not get 2nd dose yet). At the time of the report, INFLUENZA ("got sick with the flu" around the time of their scheduled 2nd dose which was 19Jun2021) and PRODUCT DOSE OMISSION ISSUE (Did not get 2nd dose yet) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Relevant concomitant product usage were not reported by the reporter. No treatment details were added.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received a dose of the Moderna COVID-19 Vaccine that expired on July 25th; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received a dose of the Moderna COVID-19 Vaccine that expired on July 25th) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received a dose of the Moderna COVID-19 Vaccine that expired on July 25th). On 27-Jul-2021, EXPIRED PRODUCT ADMINISTERED (Received a dose of the Moderna COVID-19 Vaccine that expired on July 25th) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication information were provided.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Intermenstrual bleeding
Clinical narrative: Breakthrough bleeding; This spontaneous case was reported by a consumer and describes the occurrence of INTERMENSTRUAL BLEEDING (Breakthrough bleeding) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Menopause.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INTERMENSTRUAL BLEEDING (Breakthrough bleeding). At the time of the report, INTERMENSTRUAL BLEEDING (Breakthrough bleeding) outcome was unknown.            No Concomitant medications were reported. No Treatment information was reported.   Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: Adverse event, Interchange of vaccine products
Clinical narrative: Got Pfizer vaccine and now Moderna's; Possible side effects; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Got Pfizer vaccine and now Moderna's) and ADVERSE EVENT (Possible side effects) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Got Pfizer vaccine and now Moderna's) and ADVERSE EVENT (Possible side effects). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Got Pfizer vaccine and now Moderna's) had resolved and ADVERSE EVENT (Possible side effects) outcome was unknown.            No concomitant medications were provided by the reporter.  No treatment information was provided by the reporter.
Sex: U
Vaccine: COVID19
Symptoms: Accidental overdose
Clinical narrative: Participant received 1ml rather than 0.5ml dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL OVERDOSE (Participant received 1ml rather than 0.5ml dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 milliliter. On an unknown date, the patient experienced ACCIDENTAL OVERDOSE (Participant received 1ml rather than 0.5ml dose). At the time of the report, ACCIDENTAL OVERDOSE (Participant received 1ml rather than 0.5ml dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment information was reported by reporter.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea
Clinical narrative: After receiving 1st dose, 3 days later he experienced shortness of breath for 1 hour; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (After receiving 1st dose, 3 days later he experienced shortness of breath for 1 hour) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 050C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jun-2021, the patient experienced DYSPNOEA (After receiving 1st dose, 3 days later he experienced shortness of breath for 1 hour). The patient was treated with IBUPROFEN at a dose of 600 mg every eight hours. At the time of the report, DYSPNOEA (After receiving 1st dose, 3 days later he experienced shortness of breath for 1 hour) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The concomitant medication was not reported.     This case was linked to MOD-2021-270520 (Patient Link).
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Rash, Swelling, Vaccination site reaction
Clinical narrative: Covid arm centered on the vaccination site which she described as reddening, the size of a grapefruit; she described as reddening; the size of a grapefruit; a large rash about the size of grapefruit; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (Covid arm centered on the vaccination site which she described as reddening, the size of a grapefruit), ERYTHEMA (she described as reddening), SWELLING (the size of a grapefruit) and RASH (a large rash about the size of grapefruit) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040AZ1A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma (Patient reported that animal dander causes asthma.), Hay fever (Patient reported that dust causes hay fever.) and Allergy to animal dander.    On 09-Mar-2021 at 4:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. In 2021, the patient experienced VACCINATION SITE REACTION (Covid arm centered on the vaccination site which she described as reddening, the size of a grapefruit). On an unknown date, the patient experienced ERYTHEMA (she described as reddening), SWELLING (the size of a grapefruit) and RASH (a large rash about the size of grapefruit). At the time of the report, VACCINATION SITE REACTION (Covid arm centered on the vaccination site which she described as reddening, the size of a grapefruit) outcome was unknown and ERYTHEMA (she described as reddening), SWELLING (the size of a grapefruit) and RASH (a large rash about the size of grapefruit) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications reported. No treatment medications reported.   This case was linked to MOD-2021-270465.   Most recent FOLLOW-UP information incorporated above includes: On 05-Aug-2021: Follow up received on 5-Aug-2021. Updated patient demographics, medical history, product start time, patient route of administration. Added new event rash.
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Chest pain, Flushing, Heart rate, Malaise
Clinical narrative: mid-sternal chest pain; felt flushed; didn't feel right; This spontaneous case was reported by a patient and describes the occurrence of CHEST PAIN (mid-sternal chest pain), FLUSHING (felt flushed) and MALAISE (didn't feel right) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046B21A and 007B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Apr-2021, the patient experienced CHEST PAIN (mid-sternal chest pain), FLUSHING (felt flushed) and MALAISE (didn't feel right). On 14-Apr-2021, CHEST PAIN (mid-sternal chest pain), FLUSHING (felt flushed) and MALAISE (didn't feel right) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Apr-2021, Blood pressure measurement: elevated (High) Elevated. On 14-Apr-2021, Heart rate: elevated (High) Elevated.         No concomitant products were reported.  No treatment products were reported.  Patient's symptoms subsided after about 30 minutes without any treatments and she was sent home. The physician did not provide her an explanation for her symptoms. She was well hydrated and had eaten that day.     Reporter did not allow further contact
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Fatigue
Clinical narrative: Dizziness; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness) and FATIGUE (Fatigue) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 091d21a) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (Dizziness) and FATIGUE (Fatigue). At the time of the report, DIZZINESS (Dizziness) and FATIGUE (Fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were reported. No treatment medications were reported.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Erythema, Headache, Swelling, Urticaria, Vaccination site urticaria
Clinical narrative: patient experienced a similar set of hives on the left arm; Hives his right foot, ankle, knee and calf; Red; Swollen; Headache; This spontaneous case was reported by a patient and describes the occurrence of HEADACHE (Headache), URTICARIA (Hives his right foot, ankle, knee and calf), ERYTHEMA (Red), SWELLING (Swollen) and VACCINATION SITE URTICARIA (patient experienced a similar set of hives on the left arm) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jul-2021, the patient experienced HEADACHE (Headache). On 14-Jul-2021, the patient experienced URTICARIA (Hives his right foot, ankle, knee and calf), ERYTHEMA (Red) and SWELLING (Swollen). On an unknown date, the patient experienced VACCINATION SITE URTICARIA (patient experienced a similar set of hives on the left arm). The patient was treated with IBUPROFEN at an unspecified dose and frequency; HYDROCORTISONE at an unspecified dose and frequency; ALCOHOL at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, HEADACHE (Headache), URTICARIA (Hives his right foot, ankle, knee and calf), ERYTHEMA (Red), SWELLING (Swollen) and VACCINATION SITE URTICARIA (patient experienced a similar set of hives on the left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.
Sex: U
Vaccine: COVID19
Symptoms: Dyspnoea
Clinical narrative: Im recived my firts dosis of moderna covid 19 vaccine and i have breathless is normal; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Im recived my firts dosis of moderna covid 19 vaccine and i have breathless is normal) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (Im recived my firts dosis of moderna covid 19 vaccine and i have breathless is normal). At the time of the report, DYSPNOEA (Im recived my firts dosis of moderna covid 19 vaccine and i have breathless is normal) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   No concomitant medications were not reported. No treatment medications were not provided.
Sex: U
Vaccine: COVID19
Symptoms: Dyspnoea
Clinical narrative: i got breathless like in 2 weeks; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (i got breathless like in 2 weeks) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (i got breathless like in 2 weeks). At the time of the report, DYSPNOEA (i got breathless like in 2 weeks) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant product use was reported No treatment information was provided   Reporter did not allow further contact
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Blister, Erythema, Fatigue, Pain, Pain in extremity
Clinical narrative: "bulla"; Arm is sore; Pain; Very red; Itchy; Rash; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of BLISTER ("bulla"), PAIN IN EXTREMITY (Arm is sore), PAIN (Pain), ERYTHEMA (Very red) and PRURITUS (Itchy) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036C21A and 024C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 05-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BLISTER ("bulla"), PAIN IN EXTREMITY (Arm is sore), PAIN (Pain), ERYTHEMA (Very red), PRURITUS (Itchy), RASH (Rash) and FATIGUE (Fatigue). The patient was treated with VITAMIN C + E3 for Adverse event, at a dose of 1 dosage form; FISH OIL for Adverse event, at a dose of 1 dosage form; VITAMIN B COMPLEX for Adverse event, at a dose of 1 dosage form and ZINC for Adverse event, at an unspecified dose and frequency. At the time of the report, BLISTER ("bulla"), PAIN IN EXTREMITY (Arm is sore), PAIN (Pain), ERYTHEMA (Very red), PRURITUS (Itchy), RASH (Rash) and FATIGUE (Fatigue) outcome was unknown.            No concomitant medication was reported. She is also doing organic juicing and exercising. She eats well and has been avoiding sunlight since she stated that's she can't have UV on her rash.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: follow up received contains non significant information.She heard about other people having their wounds not healed in 3-4 weeks. One person has Moderna vaccine. On 27-Jul-2021: follow up received contains non significant information.She heard about other people having their wounds not healed in 3-4 weeks. One person has Moderna vaccine.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: "bulla"; Arm is sore; Pain; Very red; Itchy; Rash; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of BLISTER ("bulla"), PAIN IN EXTREMITY (Arm is sore), PAIN (Pain), ERYTHEMA (Very red) and PRURITUS (Itchy) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036C21A and 024C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 05-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BLISTER ("bulla"), PAIN IN EXTREMITY (Arm is sore), PAIN (Pain), ERYTHEMA (Very red), PRURITUS (Itchy), RASH (Rash) and FATIGUE (Fatigue). The patient was treated with VITAMIN C + E3 for Adverse event, at a dose of 1 dosage form; FISH OIL for Adverse event, at a dose of 1 dosage form; VITAMIN B COMPLEX for Adverse event, at a dose of 1 dosage form and ZINC for Adverse event, at an unspecified dose and frequency. At the time of the report, BLISTER ("bulla"), PAIN IN EXTREMITY (Arm is sore), PAIN (Pain), ERYTHEMA (Very red), PRURITUS (Itchy), RASH (Rash) and FATIGUE (Fatigue) outcome was unknown.            No concomitant medication was reported. She is also doing organic juicing and exercising. She eats well and has been avoiding sunlight since she stated that's she can't have UV on her rash.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: follow up received contains non significant information.She heard about other people having their wounds not healed in 3-4 weeks. One person has Moderna vaccine. On 27-Jul-2021: follow up received contains non significant information.She heard about other people having their wounds not healed in 3-4 weeks. One person has Moderna vaccine.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Pruritus, Vaccination site pain, Vaccination site pruritus
Clinical narrative: Then 10 days later, her arm developed redness (the size of a quarter); 10 days later, her arm developed redness (the size of a quarter) and itchiness; Sore arm at injection site; Mild itchiness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore arm at injection site), VACCINATION SITE PRURITUS (Mild itchiness at injection site), ERYTHEMA (Then 10 days later, her arm developed redness (the size of a quarter)) and PRURITUS (10 days later, her arm developed redness (the size of a quarter) and itchiness) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jul-2021, the patient experienced VACCINATION SITE PAIN (Sore arm at injection site) and VACCINATION SITE PRURITUS (Mild itchiness at injection site). On 28-Jul-2021, the patient experienced ERYTHEMA (Then 10 days later, her arm developed redness (the size of a quarter)) and PRURITUS (10 days later, her arm developed redness (the size of a quarter) and itchiness). At the time of the report, VACCINATION SITE PAIN (Sore arm at injection site), VACCINATION SITE PRURITUS (Mild itchiness at injection site), ERYTHEMA (Then 10 days later, her arm developed redness (the size of a quarter)) and PRURITUS (10 days later, her arm developed redness (the size of a quarter) and itchiness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported by reporter  Treatment information was not provided by reporter   Reporter did not allow further contact
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Joint swelling, Paraesthesia
Clinical narrative: Ankle swelling; Tingling in both feet; left leg is numb waist down; This spontaneous case was reported by a consumer and describes the occurrence of JOINT SWELLING (Ankle swelling), PARAESTHESIA (Tingling in both feet) and HYPOAESTHESIA (left leg is numb waist down) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jul-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Jul-2021, the patient experienced JOINT SWELLING (Ankle swelling), PARAESTHESIA (Tingling in both feet) and HYPOAESTHESIA (left leg is numb waist down). At the time of the report, JOINT SWELLING (Ankle swelling), PARAESTHESIA (Tingling in both feet) and HYPOAESTHESIA (left leg is numb waist down) outcome was unknown.            Concomitant information was not provided.  Treatment information was not provided.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Myalgia
Clinical narrative: Tired; chillness (not much ); soreness due to the shot; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Tired), CHILLS (chillness (not much )) and MYALGIA (soreness due to the shot) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (Tired), CHILLS (chillness (not much )) and MYALGIA (soreness due to the shot). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, FATIGUE (Tired), CHILLS (chillness (not much )) and MYALGIA (soreness due to the shot) outcome was unknown.            No concomitant medication reported.   This case was linked to MOD-2021-207481 (Patient Link).
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Arm pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm pain) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Arm pain). At the time of the report, PAIN IN EXTREMITY (Arm pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. Treatment information was unknown.   This case was linked to MOD-2021-270272 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: Extremely tired; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Extremely tired) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (Extremely tired). At the time of the report, FATIGUE (Extremely tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.   No treatment information was provided.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Accidental overdose, Hyperhidrosis, Pallor
Clinical narrative: sweating; face looked kind of pale; pharmacist said that the dose was 0.7 ml; This spontaneous case was reported by a consumer and describes the occurrence of ACCIDENTAL OVERDOSE (pharmacist said that the dose was 0.7 ml), HYPERHIDROSIS (sweating) and PALLOR (face looked kind of pale) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 059E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .7 dosage form. On 27-Jul-2021, the patient experienced ACCIDENTAL OVERDOSE (pharmacist said that the dose was 0.7 ml). On 28-Jul-2021, the patient experienced HYPERHIDROSIS (sweating) and PALLOR (face looked kind of pale). At the time of the report, ACCIDENTAL OVERDOSE (pharmacist said that the dose was 0.7 ml), HYPERHIDROSIS (sweating) and PALLOR (face looked kind of pale) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided/unknown by the reporter. Treatment product use was not provided/unknown by the reporter.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness
Clinical narrative: Patient experienced: leg stiffened; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULOSKELETAL STIFFNESS (Patient experienced: leg stiffened) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Stiffness. Concurrent medical conditions included Drug allergy, Spice allergy and Multiple sclerosis. Concomitant products included BACLOFEN, DALFAMPRIDINE and LACTOBACILLUS ACIDOPHILUS (FLORASTOR [LACTOBACILLUS ACIDOPHILUS]) for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MUSCULOSKELETAL STIFFNESS (Patient experienced: leg stiffened). At the time of the report, MUSCULOSKELETAL STIFFNESS (Patient experienced: leg stiffened) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medication information was provided.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Rash erythematous, Rash papular, Rash pruritic, Skin warm
Clinical narrative: itchy rash (Left arm); raised rash (Left arm); red rash (Left arm); Hot rash,warm rash (Left arm); giant rash,,2 inch by 4 inch rash (Left arm); This spontaneous case was reported by a consumer and describes the occurrence of RASH PRURITIC (itchy rash (Left arm)), RASH PAPULAR (raised rash (Left arm)), RASH ERYTHEMATOUS (red rash (Left arm)), SKIN WARM (Hot rash,warm rash (Left arm)) and RASH (giant rash,,2 inch by 4 inch rash (Left arm)) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Mar-2021, the patient experienced RASH PRURITIC (itchy rash (Left arm)), RASH PAPULAR (raised rash (Left arm)), RASH ERYTHEMATOUS (red rash (Left arm)), SKIN WARM (Hot rash,warm rash (Left arm)) and RASH (giant rash,,2 inch by 4 inch rash (Left arm)). At the time of the report, RASH PRURITIC (itchy rash (Left arm)), RASH PAPULAR (raised rash (Left arm)), RASH ERYTHEMATOUS (red rash (Left arm)), SKIN WARM (Hot rash,warm rash (Left arm)) and RASH (giant rash,,2 inch by 4 inch rash (Left arm)) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment medications were provided by the reporter.   This case was linked to MOD-2021-270439 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Illness
Clinical narrative: everyone else was sick; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (everyone else was sick) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (everyone else was sick). At the time of the report, ILLNESS (everyone else was sick) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment medications were provided by the reporter.
Age: 15.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, Product administered to patient of inappropriate age
Clinical narrative: administered an expired vaccine; administered the vaccine to a 15 year old; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered an expired vaccine) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (administered the vaccine to a 15 year old) in a 15-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 ml. On 29-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (administered an expired vaccine) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (administered the vaccine to a 15 year old). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered an expired vaccine) and PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (administered the vaccine to a 15 year old) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: More than 35 days since first dose; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 35 days since first dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 35 days since first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 35 days since first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No current disease and concomitant medication information were provided. No treatment information provided.
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient received second dose of the Moderna COVID-19 vaccine 19 days after the first dose.; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose of the Moderna COVID-19 vaccine 19 days after the first dose.) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 0400C21A and 040C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Jul-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose of the Moderna COVID-19 vaccine 19 days after the first dose.). On 28-Jul-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose of the Moderna COVID-19 vaccine 19 days after the first dose.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported No treatment medications were reported. No lab data was provided by the reporter
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Memory impairment, Miliaria, Rash
Clinical narrative: Does not remember which arm/ exact date not remembered; it might be heat rash; Rash on the palms of hands, arms, and legs after second shot; Small bump on the skin after second shot; This spontaneous case was reported by a consumer and describes the occurrence of MEMORY IMPAIRMENT (Does not remember which arm/ exact date not remembered), MILIARIA (it might be heat rash), RASH (Rash on the palms of hands, arms, and legs after second shot) and RASH (Small bump on the skin after second shot) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Allergy NOS. Concomitant products included LEVOCETIRIZINE DIHYDROCHLORIDE (XYZAL) and HYDROXYZINE for an unknown indication.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced RASH (Small bump on the skin after second shot). In April 2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced RASH (Rash on the palms of hands, arms, and legs after second shot). On an unknown date, the patient experienced MEMORY IMPAIRMENT (Does not remember which arm/ exact date not remembered) and MILIARIA (it might be heat rash). The patient was treated with TRIAMCINOLONE ACETONIDE at a dose of 1 dosage form. In March 2021, RASH (Small bump on the skin after second shot) had resolved. At the time of the report, MEMORY IMPAIRMENT (Does not remember which arm/ exact date not remembered) outcome was unknown and MILIARIA (it might be heat rash) and RASH (Rash on the palms of hands, arms, and legs after second shot) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication included Allergy shots scheduled 03 Feb 2021, 17 Feb 2021, 04 Mar 2021, 19 Mar 2021, 05 Apr 2021, then every 2 weeks until 08 Jun 2021 and every 3 weeks thereafter.  On 08 Jul 2021 Patient visited an Allergist, who Prescribed Triamcinolone Acetonide Cream and did not work again patient visited a Dermatologist who has prescribed the same medication.
Sex: F
Vaccine: COVID19
Symptoms: Nervousness, Skin mass, Vaccination complication
Clinical narrative: got bumps; couldn't stop shaking; bad reaction; This spontaneous case was reported by a consumer and describes the occurrence of SKIN MASS (got bumps), NERVOUSNESS (couldn't stop shaking) and VACCINATION COMPLICATION (bad reaction) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SKIN MASS (got bumps), NERVOUSNESS (couldn't stop shaking) and VACCINATION COMPLICATION (bad reaction). At the time of the report, SKIN MASS (got bumps), NERVOUSNESS (couldn't stop shaking) and VACCINATION COMPLICATION (bad reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported. Treatment information was also not reported.   Reporter did not allow further contact
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Ear congestion, Headache, Pain in extremity, Peripheral swelling
Clinical narrative: a recurring and debilitating headache; Stuffiness in ears after both doses; Arm swelling; Arm soreness/ soreness in right arm; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Arm swelling), HEADACHE (a recurring and debilitating headache), PAIN IN EXTREMITY (Arm soreness/ soreness in right arm) and EAR CONGESTION (Stuffiness in ears after both doses) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 0022C21A and 051C21A,) for COVID-19 vaccination.     No Medical History information was reported.   On 26-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-May-2021, the patient experienced PERIPHERAL SWELLING (Arm swelling) and PAIN IN EXTREMITY (Arm soreness/ soreness in right arm). On an unknown date, the patient experienced HEADACHE (a recurring and debilitating headache) and EAR CONGESTION (Stuffiness in ears after both doses). At the time of the report, PERIPHERAL SWELLING (Arm swelling), HEADACHE (a recurring and debilitating headache), PAIN IN EXTREMITY (Arm soreness/ soreness in right arm) and EAR CONGESTION (Stuffiness in ears after both doses) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No concomitant medications were provided by the reporter.  Treatment information was not provided.   This case was linked to MOD-2021-270799 (Patient Link).
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: vaccinated from a vial which was first punctured 22 hours before the vaccination; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccinated from a vial which was first punctured 22 hours before the vaccination) in an 81-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 053C21A) for COVID-19 immunisation.     No Medical History information was reported.    On 27-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccinated from a vial which was first punctured 22 hours before the vaccination). On 27-Jul-2021, EXPIRED PRODUCT ADMINISTERED (vaccinated from a vial which was first punctured 22 hours before the vaccination) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medications were provided It was reported that the patient had not developed any side effects. No treatment medications were provided.
Sex: U
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Missed dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Its more than 3 months but patient has not taken second dose yet. Concomitant medications were not provided. Treatment information was not provided.